alpha-aminopyridine has been researched along with vardenafil dihydrochloride in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lücking, U; Sirvent, JA | 1 |
| Arancio, O; Gulisano, W; Palmeri, A; Puzzo, D; Tropea, MR | 1 |
| Bolsius, YG; Havekes, R; Heckman, PRA; Meerlo, P; Prickaerts, J; Raven, F; Roig Kuhn, F | 1 |
3 other study(ies) available for alpha-aminopyridine and vardenafil dihydrochloride
| Article | Year |
|---|---|
Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates.
Topics: Aminopyridines; Ataxia Telangiectasia Mutated Proteins; Cyclin-Dependent Kinases; Drug Design; Estradiol; Fulvestrant; Imatinib Mesylate; Piperazines; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Sulfoxides; Vardenafil Dihydrochloride | 2017 |
Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Protein Precursor; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Cyclopropanes; Disease Models, Animal; Female; Humans; Male; Memory; Mice, Transgenic; Nootropic Agents; Phosphodiesterase Inhibitors; Random Allocation; Vardenafil Dihydrochloride | 2018 |
Phosphodiesterase inhibitors roflumilast and vardenafil prevent sleep deprivation-induced deficits in spatial pattern separation.
Topics: Aminopyridines; Animals; Benzamides; Cyclopropanes; Hippocampus; Male; Memory Disorders; Mice; Phosphodiesterase 4 Inhibitors; Sleep Deprivation; Spatial Memory; Vardenafil Dihydrochloride | 2020 |